{"id":"NCT04490499","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)","officialTitle":"A Hepatitis B Vaccine Challenge Study to Demonstrate the Durability of Protection Against Hepatitis B Virus Infection in Healthy Children Vaccinated Approximately 9 Years Previously With a 2- or 3-Dose Infant Series and Toddler Dose of Vaxelis®","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-09-02","primaryCompletion":"2020-12-29","completion":"2020-12-29","firstPosted":"2020-07-29","resultsPosted":"2021-09-05","lastUpdate":"2022-07-27"},"enrollment":207,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Hepatitis B"],"interventions":[{"type":"BIOLOGICAL","name":"HBVAXPRO™","otherNames":["Hepatitis B virus (HBV) vaccine; V232"]}],"arms":[{"label":"HBVAXPRO™","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to demonstrate the durability of protection against hepatitis B virus (HBV) infection approximately 8-9 years after vaccination with Vaxelis®. This is an estimation study, and no formal hypothesis testing was performed.","primaryOutcome":{"measure":"Percentage of Participants With a Protective Hepatitis B Surface Antibody Level of ≥10 Milli International Units/mL (mIU/mL) at 30 Days Post-Challenge With HBVAXPRO™","timeFrame":"Day 30","effectByArm":[{"arm":"HBVAXPRO™","deltaMin":99.5,"sd":97.3}],"pValues":[]},"eligibility":{"minAge":"8 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":7},"locations":{"siteCount":10,"countries":["Finland"]},"refs":{"pmids":["35653552"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":205},"commonTop":[]}}